Bli medlem
Bli medlem

Du är här

2014-04-22

Genovis AB: Genovis AB (publ) Annual General Meeting

The shareholders of Genovis AB (publ) are hereby invited to the Annual
General Meeting at 4:30 pm on

Tuesday, May 20, 2014 at Scheelevägen 2, Medicon Village in Lund.

4:00 - 4:20 pm Registration

4:30 pm Opening of the Annual General Meeting

Light refreshments will be served after the meeting.

Proposed Agenda

1. Opening of the Meeting

2. Election of Chairman of the Meeting

3. Approval of the voting list

4. Approval of the agenda.

5. Election of one or two persons to verify the minutes.

6. Determination as to whether the Meeting has been duly convened.

7. Presentation of the Annual Report and the Audit Report as well as
the Consolidated Accounts and the Audit Report for the Group.

8. Speech by the Chief Executive Officer, after which shareholders
will have the opportunity to ask questions of the CEO, the Chairman
of the Board and the auditor.

9. Resolutions

a) on adoption of the income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet

b) on allocation of the Company's result in accordance with the adopted balance sheet

c) on discharge from liability of the Directors and the Chief Executive Officer

10. Determination of the number of Board members and deputy members to
be elected by the Meeting.

11. Determination of fees to the Board of the Board of Directors.

12. Determination of remuneration to the auditor.

13. Election of the Board of Directors and Chairman of the Board.

14. Appointment of members to the Nomination Committee and adoption of
guidelines for the Nomination Committee.

15. The Board of Directors' proposal for a motion regarding
remuneration guidelines for senior executives.

16. The Board's proposal for a motion on the issuance of warrants to
subscribe for shares.

17. Other matters to be considered at the Annual General Meeting in
accordance with the Swedish Companies' Act or the Articles of
Association.

18. Authorization of the Chief Executive Officer to make such formal
adjustments to the resolutions as may be necessary in conjunction
with registration and implementation thereof.

19. Closing of the Meeting.

Motions:

Item 2 Proposal to chair the meeting

The Nomination Committee proposes that attorney Arne Källén chair the
meeting.

Item 12 Determination of remuneration to the auditor

The Nomination Committee proposes that remuneration of the auditors
shall be paid on approved account.

Item 14 Appointment of members to the Nomination Committee and
adoption of guidelines for the Nomination Committee

The Nomination Committee proposes that the Committee for the 2015 AGM
will consist of representatives of the four largest shareholders at
September 30, 2014, who are not members of the Board. The Nomination
Committee shall appoint a chairman from among its members. It is
incumbent upon the Chairman of the Board to convene the Nomination
Committee. Should a shareholder decline to participate in the
committee the right to appoint a representative shall be transferred
to the next largest shareholder not represented in the committee. If
deemed appropriate as a result of ownership changes, the Nomination
Committee shall invite additional shareholders to join the Nomination
Committee, though the total number of members may not exceed five. In
the event a member of the Nomination Committee leaves the Committee
before its work is completed, the Chairman of the Board, if the
Nomination Committee deems necessary, shall invite the same
shareholder or, if the latter is no longer one of the major
shareholders, the shareholder next entitled, in terms of size of
shareholding, to appoint a replacement Such a change shall be
announced on the Company's website.

The Nomination Committee will prepare proposals for the 2015 Annual
General Meeting for resolution as regards chairman at the meeting,
Chairman of the Board and other directors, remuneration of directors
and auditors, and principles for appointing the Nomination Committee.
The Nomination Committee mandate runs until a new committee is
appointed.

The Nomination Committee proposes that remuneration will only be paid
for direct costs associated with the assignment.

Item 15 The Board of Directors' proposal for a motion regarding
remuneration guidelines for senior executives

The Board of Directors proposes that the AGM adopts the following
guidelines for remuneration to senior executives.

These guidelines are valid for employment agreements entered into
after the guidelines are approved by the AGM, and for amendments made
afterward to existing employment agreements. The basic principle is
that remuneration and other terms of employment for the management
and CEO will be competitive to ensure that Genovis AB can attract and
retain senior executives.

Fixed remuneration policy

The fixed remuneration to the management and the Chief Executive
Officer should be competitive and be based on the individual areas of
responsibility and performance.

Variable remuneration policy

Variable compensation will be limited and linked to predetermined
measurable criteria designed to promote long-term value creation for
the company. Variable compensation may not exceed a maximum of 25%
percent of the fixed salary and will be set per fiscal year.

The Board will consider on a yearly basis whether or not to propose a
share-related or market value-related incentive program to the Annual
General Meeting. The Annual General Meeting makes the decisions
regarding such incentive programs.

Conditions for non-monetary benefits, pensions, termination, and
severance pay

Pensions

Management and the CEO are entitled to a defined-contribution pension.

Termination and severance pay

For the CEO the notice period is 12 months for the Company and 6
months for the individual. For management personnel the notice
period is 6 months for the Company and 6 months for the individual.
Moreover, assuming that the Company gave notice of termination, in
certain cases the CEO may be offered 12 months of severance pay. The
Board of Directors may depart from these guidelines if there are
particular reasons in an individual case.

The company's undertaking in relation to senior executives and the
chief executive may amount to a maximum of SEK 3,828,810.

Item 16 The Board's proposal for a motion on the issuance of warrants
to subscribe for shares.

The Board of Directors of Genovis ("the Company") proposes that the
AGM resolves in favor of issuance of a maximum of 450,000 warrants.
Each warrant entitles the holder to subscribe for one (1) new share
in Genovis.

The price at which new shares may be subscribed for shall correspond
to a sum that amounts to 150 percent of the volume-weighted average
price paid for the Company's share, which is listed on First North,
during the period from May 6, 2014 up until May 19, 2014, though no
lower than a subscription price corresponding to the par value of the
share.

Subscription for new shares will take place during the period from
April 1, 2017 through June 30, 2017.

The warrants may only be subscribed, with deviation from shareholders'
preferential rights, by GeccoDots AB, a wholly-owned subsidiary ("the
Subsidiary") of Genovis, given that the AGM approves the resolution
on the issuance.

The warrants will be issued without consideration to the Subsidiary.
It is intended that the Subsidiary subsequently, on one or more
occasions, will transfer the warrants to the CEO and key personnel of
great value to the Company's future development ("Participants") as
part of a long-term incentive program established by the Company.

For the warrants that the Subsidiary transfers to the Participants,
they shall pay a premium corresponding to the prevailing market value
according to an independent valuation using the Black-Scholes
formula. The Board proposes that the Meeting approve the Subsidiary's
transfer of the warrants on the terms and conditions specified above.

The Board's reason for the above proposal, and the deviation from
shareholders' preferential rights, is that a personal long-term
ownership commitment among the employees can be expected to stimulate
increased interest in the business and the earnings trend, increased
motivation and an enhanced sense of loyalty to the Company, which the
Board considers to be beneficial for the Company and its
shareholders. The Board therefore believes that the offer is
beneficial to the Company and its shareholders.

Assuming full exercise of the warrants, share capital will increase by
about SEK 180,000, corresponding to a dilution effect of
approximately 2.0 percent of the total number of shares and votes in
the Company.

The Board proposes that the AGM resolves that the Board or the Board
designee is hereby authorized to determine the amount of the issue
price in accordance with the above decision and adapt the conditions
accordingly, and to otherwise make minor adjustments to the
resolutions above that may be required for registration with the
Swedish Companies Registration Office and Euroclear.

Decisions under this item on the agenda require support of
shareholders representing at least nine tenths of both cast votes and
shares represented at the meeting.

Right to attend the Annual General Meeting

Shareholders who are listed in a printout of the shareholders'
register produced by Euroclear Sweden AB (formerly VPC AB)

on May 14, 2014, and have notified the Company of their intention to
attend the Annual General Meeting by 12 noon on May 14, 2014 at the
latest are entitled to attend Genovis' Annual General Meeting.

Recording in shareholders' register

Only owner-registered holdings are listed in the register maintained
by Euroclear Sweden AB (formerly VPC AB). Shareholders with
nominee-registered shares must temporarily register their shares in
their own name to be entitled to participate in the Annual General
Meeting. Shareholders who have nominee-registered shares must request
temporary owner-registration, so-called voting-right registration,
with their bank or broker holding the shares a couple of banking days
prior to May 14, 2014.

Registration

Register to participate at the Annual General Meeting:

· Address: Box 790, S-220 07 Lund, Sweden
· P: +46 (0)46-10 12 30
· F: +46 (0)46-12 80 20
· E-mail: info@genovis.com

Include the following information when registering

· name/company name
· personal identification number/corporate registration number
· addre...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.